Startups 2024
Emerging Startup
Atheon Bio
Innovation & Business Idea
Despite the emergence of immuno-oncology therapies, low response rates and resistance continue to pose as an obstacle. PD-(L)1 has been revolutionary in immuno-oncology but has significant medical unmet needs. TME (tumor microenvironment) plays essential role in tumor growth and is the cause of refractory and resistance. Atheon Bio provides the solution. We are developing the first-in-class PD-(L)1 Sensitizer.
Contact
Sue Soheui Choe, Ph.D., J.D.
